A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia

Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine. This phase I study evaluated nintedanib in combination with low-dos...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :PLoS One
Главные авторы: Schliemann, Christoph, Gerss, Joachim, Wiebe, Stefanie, Mikesch, Jan-Henrik, Knoblauch, Nicola, Sauer, Tim, Angenendt, Linus, Kewitz, Tobias, Urban, Marc, Butterfass-Bahloul, Trude, Edemir, Sabine, Vehring, Kerstin, Müller-Tidow, Carsten, Berdel, Wolfgang E., Krug, Utz
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2016
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5055288/
https://ncbi.nlm.nih.gov/pubmed/27716819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0164499
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы